<p>/PRNewswire/ -- Kodiak Sciences Inc.（納斯達克：KOD）是一家專注於視網膜的前商業生物技術公司，致力於研究、開發和商業化變革性治療藥物，今天宣佈完成其之前宣佈的 800 萬股普通股的承銷公開發行，其中包括根據承銷商完全行使其購買額外股份的選擇權出售的 1,043,478 股，公開發行價格為每股 23.00 美元。Kodiak Sciences 從此次發行中獲得的總收益約為 1.84 億美元，未扣除承銷折扣和佣金以及 Kodiak Sciences 應支付的估計發行費用。</p>
<p>摩根大通、傑富瑞、Evercore ISI 和瑞銀投資銀行擔任此次發行的聯合賬簿管理人。</p>
<p>Kodiak 的董事長兼首席執行官 Victor Perlroth 博士表示：“我們很高興成功完成此次公開發行，這增強了我們的財務狀況，因為我們正在推進 KSI-101、KSI-501 和 tarcocimab 這三項晚期臨牀資產的重要第三階段頂線結果。此次交易經過深思熟慮的結構設計，反映了我們對資本形成的嚴謹態度以及我們對長期股東價值的持續關注。”</p>
<p>上述股份是根據 Kodiak Sciences 之前向證券交易委員會（“SEC”）提交的 S-3 表格的貨架註冊聲明進行發行的，包括基礎招股説明書，該註冊聲明於 2023 年 6 月 2 日獲得 SEC 的有效確認。與此次發行相關的最終招股説明書補充及隨附招股説明書已向 SEC 提交，並可在 SEC 網站 http://www.sec.gov 上免費獲取。與此次發行相關的最終招股説明書補充及隨附招股説明書的副本可從以下地址獲得：摩根大通證券有限責任公司，注意：Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，通過電子郵件聯繫 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；傑富瑞有限責任公司，注意：股權承銷招股説明書部門，520 Madison Avenue，New York，New York 10022，電話：（877）821-7388，或通過電子郵件聯繫 prospectus_department@jefferies.com；Evercore Group L.L.C.，注意：股權資本市場，55 East 52nd Street，35th Floor，New York，NY 10055，或撥打電話 888-474-0200，或通過電子郵件聯繫 ecm.prospectus@evercore.com；或瑞銀證券有限責任公司，注意：招股説明書部門，瑞銀投資銀行，11 Madison Avenue，New York，New York 10010，或通過電子郵件聯繫 ol-prospectus-request@ubs.com。</p>
<p>本新聞稿不構成出售要約或購買要約的徵求，也不構成在任何州或司法管轄區內出售這些證券的行為，在任何此類州或司法管轄區內，任何此類要約、徵求或銷售在註冊或資格之前均屬非法。</p>
<p><strong>關於 Kodiak Sciences Inc.</strong></p>
<p>Kodiak Sciences（納斯達克：KOD）是一家專注於視網膜的前商業生物技術公司，致力於研究、開發和商業化變革性治療藥物。我們專注於將新科學應用於下一代視網膜藥物的設計和製造，以預防和治療全球失明的主要原因。我們的 ABC®平台利用分子工程將基於蛋白質和基於化學的治療領域結合在一起，並一直是 Kodiak 發現引擎的核心。我們正在開發三個晚期臨牀項目的組合。Tarcocimab 和 KSI-501 正在兩個面向 BLA 的第三階段研究中探索視網膜血管疾病。KSI-101 是一種雙特異性蛋白，正在兩個第三階段研究中探索與炎症相關的黃斑水腫（MESI）。</p>
<p>Kodiak®、Kodiak Sciences®、ABC™、ABC Platform™和 Kodiak 標誌是 Kodiak Sciences Inc.在多個全球司法管轄區註冊的商標或商標。</p>
<p>來源：Kodiak Sciences Inc.</p>

<p>Kodiak Sciences Inc. 宣佈完成其 1.84 億美元的公開發行，發行 8,000,000 股普通股，包括承銷商對額外股份的完全行使選擇權。此次發行增強了 Kodiak 在其 KSI-101、KSI-501 和 tarcocimab 資產的 3 期臨牀試驗中的財務狀況。摩根大通、傑富瑞、Evercore ISI 和瑞銀投資銀行管理了此次發行。該股份是在向美國證券交易委員會（SEC）提交的貨架註冊聲明下發行的</p>

<p>, /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock, which includes 1,043,478 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $23.00 per share. The gross proceeds to Kodiak Sciences from the offering were approximately $184 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Kodiak Sciences.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Kodiak Sciences Inc.（納斯達克：KOD）是一家專注於視網膜的前商業生物技術公司，致力於研究、開發和商業化變革性治療藥物，今天宣佈完成其之前宣佈的 800 萬股普通股的承銷公開發行，其中包括根據承銷商完全行使其購買額外股份的選擇權出售的 1,043,478 股，公開發行價格為每股 23.00 美元。Kodiak Sciences 從此次發行中獲得的總收益約為 1.84 億美元，未扣除承銷折扣和佣金以及 Kodiak Sciences 應支付的估計發行費用。</p>
</div><p>J.P. Morgan, Jefferies, Evercore ISI and UBS Investment Bank acted as joint book-running managers for the offering.</p>
<div class="lb-trans"><p>摩根大通、傑富瑞、Evercore ISI 和瑞銀投資銀行擔任此次發行的聯合賬簿管理人。</p>
</div><p>Dr. Victor Perlroth, M.D., Chairman and CEO of Kodiak commented, &#34;we are pleased to have successfully completed this public offering, which strengthens our financial position as we execute through important Phase 3 topline readouts for all three of our late-stage clinical assets of KSI-101, KSI-501 and tarcocimab. The transaction was thoughtfully structured, reflecting our disciplined approach to capital formation and our continued focus on long-term shareholder value.&#34;</p>
<div class="lb-trans"><p>Kodiak 的董事長兼首席執行官 Victor Perlroth 博士表示：“我們很高興成功完成此次公開發行，這增強了我們的財務狀況，因為我們正在推進 KSI-101、KSI-501 和 tarcocimab 這三項晚期臨牀資產的重要第三階段頂線結果。此次交易經過深思熟慮的結構設計，反映了我們對資本形成的嚴謹態度以及我們對長期股東價值的持續關注。”</p>
</div><p>The shares described above were offered by Kodiak Sciences pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kodiak Sciences with the Securities and Exchange Commission (the &#34;SEC&#34;) and that was declared effective by the SEC on June 2, 2023. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available for free on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, telephone: (877) 821-7388, or by emailing prospectus_department@jefferies.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com; or UBS Securities LLC, Attention: Prospectus Department, UBS Investment Bank, 11 Madison Avenue, New York, New York 10010 or by email at ol-prospectus-request@ubs.com.</p>
<div class="lb-trans"><p>上述股份是根據 Kodiak Sciences 之前向證券交易委員會（“SEC”）提交的 S-3 表格的貨架註冊聲明進行發行的，包括基礎招股説明書，該註冊聲明於 2023 年 6 月 2 日獲得 SEC 的有效確認。與此次發行相關的最終招股説明書補充及隨附招股説明書已向 SEC 提交，並可在 SEC 網站 http://www.sec.gov 上免費獲取。與此次發行相關的最終招股説明書補充及隨附招股説明書的副本可從以下地址獲得：摩根大通證券有限責任公司，注意：Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，通過電子郵件聯繫 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；傑富瑞有限責任公司，注意：股權承銷招股説明書部門，520 Madison Avenue，New York，New York 10022，電話：（877）821-7388，或通過電子郵件聯繫 prospectus_department@jefferies.com；Evercore Group L.L.C.，注意：股權資本市場，55 East 52nd Street，35th Floor，New York，NY 10055，或撥打電話 888-474-0200，或通過電子郵件聯繫 ecm.prospectus@evercore.com；或瑞銀證券有限責任公司，注意：招股説明書部門，瑞銀投資銀行，11 Madison Avenue，New York，New York 10010，或通過電子郵件聯繫 ol-prospectus-request@ubs.com。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售要約或購買要約的徵求，也不構成在任何州或司法管轄區內出售這些證券的行為，在任何此類州或司法管轄區內，任何此類要約、徵求或銷售在註冊或資格之前均屬非法。</p>
</div><p><strong>About Kodiak Sciences Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Kodiak Sciences Inc.</strong></p>
</div><p>Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC® Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine. We are developing a portfolio of three late-stage clinical programs. Tarcocimab and KSI-501 are being explored in two BLA-facing Phase 3 studies in the retinal vascular diseases. KSI-101 is a bispecific protein being explored in two Phase 3 studies in Macular Edema Secondary to Inflammation (MESI).</p>
<div class="lb-trans"><p>Kodiak Sciences（納斯達克：KOD）是一家專注於視網膜的前商業生物技術公司，致力於研究、開發和商業化變革性治療藥物。我們專注於將新科學應用於下一代視網膜藥物的設計和製造，以預防和治療全球失明的主要原因。我們的 ABC®平台利用分子工程將基於蛋白質和基於化學的治療領域結合在一起，並一直是 Kodiak 發現引擎的核心。我們正在開發三個晚期臨牀項目的組合。Tarcocimab 和 KSI-501 正在兩個面向 BLA 的第三階段研究中探索視網膜血管疾病。KSI-101 是一種雙特異性蛋白，正在兩個第三階段研究中探索與炎症相關的黃斑水腫（MESI）。</p>
</div><p>Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.</p>
<div class="lb-trans"><p>Kodiak®、Kodiak Sciences®、ABC™、ABC Platform™和 Kodiak 標誌是 Kodiak Sciences Inc.在多個全球司法管轄區註冊的商標或商標。</p>
</div><p>SOURCE Kodiak Sciences Inc.</p>
<div class="lb-trans"><p>來源：Kodiak Sciences Inc.</p>
</div>

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares | KOD Stock News

Kodiak Sciences 宣佈完成 1.84 億美元普通股公開發行，其中包括承銷商全額行使購買額外股份的選擇權 | KOD 股票新聞